Intelligent Bio Solutions Inc. (INBS) Stock Price & Analysis
Intelligent Bio Solutions Inc. (INBS) rose 0.83% to USD 2.42 as of June 10, 2026 at 03:09 UTC, according to Nexqual real-time market data.
INBS last closed at USD 2.4; the session ranged USD 2.27–2.42 on volume of 39,240 shares. Market capitalization is $5.79M, with a 52-week range of USD 2.24–24.9 (NCM). Source: Nexqual, June 10, 2026 at 03:09 UTC.
Key Statistics (as of June 10, 2026 at 03:09 UTC)
| Price | USD 2.42 |
|---|---|
| Change | ▲ 0.83% (up) |
| Previous Close | USD 2.4 |
| Open | USD 2.32 |
| Day Range | USD 2.27 – 2.42 |
| 52-Week Range | USD 2.24 – 24.9 |
| Volume | 39,240 shares |
| Market Cap | $5.79M |
| Exchange | NCM |
Technical Analysis (INBS)
Nexqual's technical model rates INBS "SELL" based on 1 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:09 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 40.47 (neutral) |
| vs SMA50 | Below (USD 2.74) |
| MACD | -0.15 (negative) |
Analyst Ratings (INBS)
Wall Street analysts rate INBS "None", per Nexqual as of June 10, 2026 at 03:09 UTC.
| Consensus Rating | None |
|---|
Earnings (INBS)
Source: Nexqual, June 10, 2026 at 03:09 UTC.
Financials & Fundamentals (INBS)
| Total Revenue | $3.91M |
|---|---|
| Revenue Growth (YoY) | +45.50% |
| Gross Margin | +47.25% |
| Operating Margin | -277.33% |
| Profit Margin | -296.77% |
| ROE | -170.19% |
| Debt / Equity | 21.12 |
| Current Ratio | 2.11 |
| Total Cash | $6.86M |
| Total Debt | $1.85M |
| Free Cash Flow | $-6.49M |
Source: Nexqual, June 10, 2026 at 03:09 UTC.
Financial Health Score (INBS)
Nexqual rates Intelligent Bio Solutions Inc.'s overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:09 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $7M cash vs $2M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$11M |
| Efficiency | Critical — ROE -170%, ROA -57.3% |
Ownership (INBS)
| Insider Ownership | +3.57% |
|---|---|
| Institutional Ownership | +8.71% |
| Shares Outstanding | 2.39M |
| Float | 2.17M |
| Short % of Float | +3.83% |
Source: Nexqual, June 10, 2026 at 03:09 UTC.
Leadership (INBS)
Intelligent Bio Solutions Inc. is led by Harry Simeonidis (age 57), President & CEO, per Nexqual as of June 10, 2026 at 03:09 UTC.
| President & CEO | Harry Simeonidis (age 57) |
|---|---|
| Chief Financial Officer | Spiro Kevin Sakiris B.Bus, C.A., Dip Law (age 63) |
| Vice President of Global Quality & Operations | Callistus Sequeira |
| Vice President of Global Sales | Doug Heath |
| Vice President of Marketing | Anna Turkington |
Major Backers & Investors (INBS)
Notable institutional backers of Intelligent Bio Solutions Inc. include Armistice Capital, LLC, Alyeska Investment Group, L.p., Fidelity, according to Nexqual as of June 10, 2026 at 03:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 5.44% |
| Alyeska Investment Group, L.p. | 1.59% |
| Fidelity | 1.05% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Geode Capital | 1.2% |
| Vanguard Group | 0.65% |
Source: Nexqual, June 10, 2026 at 03:09 UTC.
From Intelligent Bio Solutions Inc.'s Latest SEC 10-K Filing (filed 2025-08-15)
Key Strengths & Strategy (as disclosed to the SEC)
- The Company operates globally with the objective of providing innovative and accessible solutions that improve the quality of life.   Our Testing Platforms   Intelligent Fingerprinting Platform: The Company's current active product is the Intelligent Fingerprinting Platform, which consists of the proprietary portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader.
- We completed a 510(k) submission in December 2024, and remain focused on securing FDA 510(k) clearance for the IFP System's opiate test system for codeine in the U.S., which will enable broader use beyond current Forensic Use Only settings.
- Approximately 292 million people used drugs worldwide in 2022, a 20% increase over the previous decade.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CDIO | Cardio Diagnostics Holdings Inc | USD 1.94 | ▼ 1.02% |
| TNON | Tenon Medical, Inc. | USD 0.62 | ▲ 2.12% |
| BDRX | Biodexa Pharmaceuticals plc | USD 3.1 | ▼ 7.74% |
| SPRC | SciSparc Ltd. | USD 9.31 | ▼ 18.62% |
| FRGT | Freight Technologies, Inc. | USD 4.5 | ▲ 6.64% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:09 UTC. This page is informational and not investment advice.